Diabetes research and clinical practice最新文献_第7页

SGLT2 inhibitors improve subclinical left ventricular systolic function independent of body mass index in patients with type 2 diabetes: A prospective strain imaging study SGLT2抑制剂改善2型糖尿病患者独立于体重指数的亚临床左心室收缩功能：一项前瞻性应变成像研究

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-03-01 Epub Date: 2026-02-07 DOI: 10.1016/j.diabres.2026.113147

Ömer Kümet , Fuat Polat , Ozan Durmaz , Veysi Can , Ahmet Ferhat Kaya , Görkem Ayhan , Emrah Özbek

{"title":"SGLT2 inhibitors improve subclinical left ventricular systolic function independent of body mass index in patients with type 2 diabetes: A prospective strain imaging study","authors":"Ömer Kümet , Fuat Polat , Ozan Durmaz , Veysi Can , Ahmet Ferhat Kaya , Görkem Ayhan , Emrah Özbek","doi":"10.1016/j.diabres.2026.113147","DOIUrl":"10.1016/j.diabres.2026.113147","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus is associated with subclinical left ventricular dysfunction. SGLT2 inhibitors demonstrate cardiovascular benefits in trials, but their effects on subclinical myocardial function and relationship to body weight in clinical practice remain unclear. This study examined global longitudinal strain (GLS) changes during SGLT2 inhibitor therapy across body mass index (BMI) categories.</div></div><div><h3>Methods</h3><div>This prospective observational cohort enrolled 614 patients newly initiated on SGLT2 inhibitors (September 2022-May 2025), stratified by BMI: normal weight (n = 300) and overweight/obesity (n = 314). Speckle tracking echocardiography assessed GLS at baseline and 6 months.</div></div><div><h3>Results</h3><div>Both groups showed significant GLS improvement (normal weight: −17.83 ± 1.30% to −19.22 ± 1.20%; overweight/obesity: −17.70 ± 1.48% to −19.05 ± 1.24%; both p < 0.001), with similar magnitude (p = 0.696). Overweight/obesity patients experienced modest BMI reduction (−0.66 kg/m<sup>2</sup>, p < 0.001); normal weight remained stable. Baseline GLS strongly predicted improvement (OR = 1.553, p < 0.001), while baseline BMI showed no association (OR = 1.000, p = 0.993).</div></div><div><h3>Conclusion</h3><div>SGLT2 inhibitor therapy was associated with similar subclinical left ventricular systolic function improvement across BMI categories. While causality cannot be established without controls and BMI imperfectly measures adiposity, findings align with randomized trial cardiovascular benefits, suggesting benefits may extend across the body weight spectrum.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"233 ","pages":"Article 113147"},"PeriodicalIF":7.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of lifestyle modification in prediabetes remission among women with isolated impaired fasting glucose: A community-based, randomised controlled trial in India 生活方式改变对孤立性空腹血糖受损女性糖尿病前期缓解的有效性：印度一项基于社区的随机对照试验

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-13 DOI: 10.1016/j.diabres.2026.113106

Elezebeth Mathews , Thakarakkattil Narayanan Nair Anand , Anjaly Joseph , Bhagiaswari Kodapally , Rajendra Pilankatta , K M Venkat Narayan , Brian Oldenburg , Kavumpurathu Raman Thankappan

{"title":"Effectiveness of lifestyle modification in prediabetes remission among women with isolated impaired fasting glucose: A community-based, randomised controlled trial in India","authors":"Elezebeth Mathews , Thakarakkattil Narayanan Nair Anand , Anjaly Joseph , Bhagiaswari Kodapally , Rajendra Pilankatta , K M Venkat Narayan , Brian Oldenburg , Kavumpurathu Raman Thankappan","doi":"10.1016/j.diabres.2026.113106","DOIUrl":"10.1016/j.diabres.2026.113106","url":null,"abstract":"<div><h3>Aims</h3><div>We evaluated the effectiveness of a lifestyle modification (LSM) intervention in prediabetes remission among women with isolated impaired fasting glucose (i-IFG).</div></div><div><h3>Methods</h3><div>We conducted a community-based, parallel-group, open-label, randomised controlled trial in Kerala, India. Women aged 30–60 years with i-IFG were randomly assigned (1:1) to receive either a 12-month LSM program or standard care (diabetes information booklet). Randomization was computer-generated with allocation concealed until assignment. The primary outcome was prediabetes remission based on oral glucose tolerance testing at 12 months. Secondary outcomes included progression to type 2 diabetes and changes in glycaemic markers, anthropometric measures, body composition, and blood pressure. Analyses followed the intention-to-treat approach.</div></div><div><h3>Results</h3><div>Of 1092 participants randomised, 1080 (98.9 %) completed the 12-month follow-up. Prediabetes remission was significantly higher in the LSM group than in controls (45.9 % vs 6.3 %; RR 7.04, 95 % CI 5.12–10.06). LSM also produced greater improvements in fasting plasma glucose (–5.2 mg/dL), HbA1c (–0.09 %), HOMA2-IR (log) (–0.38), weight (–3.7 kg), waist circumference (–1.4 cm), fat mass (–2.9 kg), and fat-free mass (+0.86 kg). The number needed to treat for prediabetes remission was 2.8 (1.8–4.0).</div></div><div><h3>Conclusion</h3><div>A structured LSM intervention effectively promotes prediabetes remission in women with i-IFG and improves cardio metabolic health.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113106"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic potential of prebiotics in modulating postprandial GLP-1, GLP-2, and glucose homeostasis in type 2 diabetes mellitus: Targeting gut dysbiosis and insulin resistance 益生元调节2型糖尿病餐后GLP-1、GLP-2和葡萄糖稳态的治疗潜力：针对肠道生态失调和胰岛素抵抗

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-12 DOI: 10.1016/j.diabres.2026.113102

Zainab Irfan , Jitu Halder , Sumon Giri , Ekbal Ali Molla , Sofia Khanam

{"title":"Therapeutic potential of prebiotics in modulating postprandial GLP-1, GLP-2, and glucose homeostasis in type 2 diabetes mellitus: Targeting gut dysbiosis and insulin resistance","authors":"Zainab Irfan , Jitu Halder , Sumon Giri , Ekbal Ali Molla , Sofia Khanam","doi":"10.1016/j.diabres.2026.113102","DOIUrl":"10.1016/j.diabres.2026.113102","url":null,"abstract":"<div><div>Type 2 diabetes mellitus is associated with gut dysbiosis, decreased microbial diversity, short-chain fatty acid synthesis, and altered GLP secretion, which are crucial for intestinal integrity, insulin sensitivity, and postprandial glucose control. Evidence from peer-reviewed mechanistic studies, observational research, clinical trials, and meta-analyses was summarised in this review. Prebiotics, an emerging potential treatment, increase the formation of SCFA during fermentation, thereby enhancing the release of GLP through FFAR2/3 signalling. This chain of events enhances glucose-dependent insulin production, inhibits glucagon secretion, delays stomach emptying, strengthens the intestinal barrier, and reduces inflammation throughout the body. Human trials demonstrate statistically significant but clinically modest improvements in HbA1c, postprandial glucose fluctuations, and an increased response to incretin-based treatments, with meta-analytic evidence reporting decreased fasting glucose and HbA1c levels. Prebiotics effect on incretin hormones in humans appears to be diverse, depending on the type, dose, duration, and baseline microbiota composition. Resistant starch and inulin-type fructans have the most consistent effects for lowering postprandial glucose. Prebiotics are viable supplementary therapy for improving glycaemic management by regulating the gut microbiota-SCFA-incretin axis. While the molecular evidence is substantial, clinical effects are moderate and diverse. Long-term microbiome-specific trials are required to understand therapeutic potential and optimise tailored therapies fully.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113102"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145974270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebral microbleeds are associated with deficits in cognitive processing speed and executive functions in middle-aged adults with type 1 diabetes 1型糖尿病中年患者脑微出血与认知处理速度和执行功能缺陷有关。

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-02 DOI: 10.1016/j.diabres.2025.113080

Iiris Kyläheiko , Aleksi Tarkkonen , Linda Kuusela , Juha Martola , Teemu I. Paajanen , Jussi Virkkala , Per-Henrik Groop , Lena M. Thorn , Turgut Tatlisumak , Jukka Putaala , Daniel Gordin , Hanna Jokinen , on behalf of the FinnDiane Study Group

{"title":"Cerebral microbleeds are associated with deficits in cognitive processing speed and executive functions in middle-aged adults with type 1 diabetes","authors":"Iiris Kyläheiko , Aleksi Tarkkonen , Linda Kuusela , Juha Martola , Teemu I. Paajanen , Jussi Virkkala , Per-Henrik Groop , Lena M. Thorn , Turgut Tatlisumak , Jukka Putaala , Daniel Gordin , Hanna Jokinen , on behalf of the FinnDiane Study Group","doi":"10.1016/j.diabres.2025.113080","DOIUrl":"10.1016/j.diabres.2025.113080","url":null,"abstract":"<div><h3>Aims</h3><div>Adults with type 1 diabetes (T1D) have an increased risk of cerebral small vessel disease (cSVD)-related brain changes already in midlife, yet their significance for cognitive functions remains poorly understood. We investigated associations between cerebral microbleeds (CMBs), white matter hyperintensities (WMHs), and cognition in individuals with T1D and without any neurological symptoms.</div></div><div><h3>Methods</h3><div>Participants (n=167; age 46.4±7.7 years) underwent cross-sectional clinical and biochemical evaluations, brain magnetic resonance imaging, and neuropsychological assessment. CMB number and topography (lobar, deep/infratentorial, or mixed location) and WMHs, quantified volumetrically, were evaluated.</div></div><div><h3>Results</h3><div>Compared to absence of CMBs, higher burden of CMBs (≥3) was associated independently of age with poorer processing speed (standardized <em>β</em> from 0.18 to 0.23, p<0.05) and executive functions (standardized <em>β</em> from 0.18 to –0.25, p<0.05), but not with episodic memory. Mild WMHs had no independent relationships with cognition. Compared to other topographies, mixed CMB location was more often negatively related to cognition (standardized <em>β</em> from 0.20 to 0.32, p<0.05).</div></div><div><h3>Conclusions</h3><div>CMBs were related to a subtle, yet systematic impairment in cognition, whereas mild WMHs were not. The results provide insight into the development of early cSVD-related cognitive changes already in midlife and suggest an increased risk of cognitive decline in T1D.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113080"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lived experience of fully closed-loop insulin delivery in adolescents with type 1 diabetes and HbA1c above target HbA1c高于目标的青少年1型糖尿病患者全闭环胰岛素输送的生活经验

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2025-12-30 DOI: 10.1016/j.diabres.2025.113078

Nithya Kadiyala , Janet Allen , Rama Lakshman , Charlotte K. Boughton , Malgorzata E. Wilinska , Ajay Thankamony , Sara Hartnell , Hood Thabit , Ruben H. Willemsen , Pratik Shah , Julia Ware , Roman Hovorka

{"title":"Lived experience of fully closed-loop insulin delivery in adolescents with type 1 diabetes and HbA1c above target","authors":"Nithya Kadiyala , Janet Allen , Rama Lakshman , Charlotte K. Boughton , Malgorzata E. Wilinska , Ajay Thankamony , Sara Hartnell , Hood Thabit , Ruben H. Willemsen , Pratik Shah , Julia Ware , Roman Hovorka","doi":"10.1016/j.diabres.2025.113078","DOIUrl":"10.1016/j.diabres.2025.113078","url":null,"abstract":"<div><h3>Aims</h3><div>The aim of this qualitative study was to explore the impact of using the CamAPS HX fully closed-loop system, which does not require carbohydrate counting, meal announcements or pre-meal bolusing, on the daily lives of adolescents with type 1 diabetes and HbA1c above the recommended target (≥7.5 % [58 mmol/mol]).</div></div><div><h3>Methods</h3><div>Twelve adolescents took part in virtual semi-structured interviews. Data was analyzed thematically using an inductive-deductive approach. Study participants also completed quality of life questionnaires.</div></div><div><h3>Results</h3><div>All interviewees reported reduced effort in managing diabetes, as they no longer needed to count carbohydrates or bolus, and worried less about their glucose levels. This led to improved quality of life, with a greater sense of freedom and normalcy, particularly around meals. A few also noted benefits in physical activity, sleep, work and social life. Interviewees expressed dissatisfaction with the algorithm’s slow response to postprandial glucose spikes, and the need for a tethered pump. Questionnaires showed no significant differences in hypoglycaemia fear or diabetes distress between study periods but reflected a positive experience with the closed-loop system.</div></div><div><h3>Conclusions</h3><div>In adolescents with type 1 diabetes, fully closed-loop insulin delivery reduced the daily burden of self-management, leading to improved quality of life.</div><div>Clinical trial registration: NCT05653050.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113078"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity 心血管疾病-代谢功能障碍相关脂肪变性肝病合并症的负担和死亡率影响

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-07 DOI: 10.1016/j.diabres.2026.113092

Siyuan Tan , Ting Huang , Zixi Zhang , Jiabao Zhou , Hao Chen , Tao Tu , Qiuzhen Lin , Yichao Xiao , Qiming Liu

{"title":"The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity","authors":"Siyuan Tan , Ting Huang , Zixi Zhang , Jiabao Zhou , Hao Chen , Tao Tu , Qiuzhen Lin , Yichao Xiao , Qiming Liu","doi":"10.1016/j.diabres.2026.113092","DOIUrl":"10.1016/j.diabres.2026.113092","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) and metabolic dysfunction–associated steatotic liver disease (MASLD) are metabolically linked, yet their combined burden and mortality impact remain underexplored.</div></div><div><h3>Methods</h3><div>Using Global Burden of Disease (GBD) 2023 data, we assessed temporal and regional trends in CVD, MASLD, and metabolic risk factors. National Health and Nutrition Examination Survey (NHANES) data were subsequently analyzed to examine the association between CVD–MASLD comorbidity and mortality using multivariable and survival models.</div></div><div><h3>Results</h3><div>From 1990 to 2023, the global burden of CVD declined steadily, whereas MASLD rose continuously, showing divergent and regionally heterogeneous trends. In high-income countries, CVD indicators decreased despite increasing MASLD burden, whereas this inverse pattern was weaker in upper–middle-income regions. In NHANES, individuals with CVD–MASLD comorbidity exhibited the highest metabolic abnormalities and mortality risk. Compared with those without comorbidities, adjusted hazard ratios were 1.68 for all-cause and 2.68 for cardiovascular mortality. Mortality rose progressively with fibrosis severity. PAF analyses showed that CVD, MASLD, and their comorbidity accounted for 13.3%, 1.3%, and 7.8% of cardiovascular deaths, respectively, totaling 22.4%. These associations demonstrated marked age-related heterogeneity.</div></div><div><h3>Conclusion</h3><div>CVD–MASLD comorbidity is an emerging global concern associated with excess mortality, emphasizing the need to incorporate MASLD screening and fibrosis evaluation into cardiovascular prevention strategies.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113092"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inverse association of insulin-like growth factor binding protein 1 with epicardial and intrathoracic adiposity in older adults: The Longenity study 胰岛素样生长因子结合蛋白1与老年人心外膜和胸内肥胖的负相关：长寿研究

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-11 DOI: 10.1016/j.diabres.2026.113099

Rohan Kankaria , J.Nicholas Charla , Kenny Ye , Leandro Slipczuk , Damini Dey , Jeffrey M. Levsky , Wanda Guzman , Daniel Amadeo , Aribah Zaidi , Jorge R. Kizer , Nir Barzilai , Sofiya Milman , Anna E. Bortnick

{"title":"Inverse association of insulin-like growth factor binding protein 1 with epicardial and intrathoracic adiposity in older adults: The Longenity study","authors":"Rohan Kankaria , J.Nicholas Charla , Kenny Ye , Leandro Slipczuk , Damini Dey , Jeffrey M. Levsky , Wanda Guzman , Daniel Amadeo , Aribah Zaidi , Jorge R. Kizer , Nir Barzilai , Sofiya Milman , Anna E. Bortnick","doi":"10.1016/j.diabres.2026.113099","DOIUrl":"10.1016/j.diabres.2026.113099","url":null,"abstract":"<div><h3>Aims</h3><div>Higher serum insulin-like growth factor binding protein 1 (IGFBP-1) is associated with insulin sensitivity and reduced risk of obesity, diabetes, and atherosclerosis. Epicardial (EAT) and intrathoracic adipose tissue (IAT) are associated with increased atherosclerosis. Whether there is an inverse association of IGFBP-1 with EAT and IAT is unknown.</div></div><div><h3>Methods</h3><div>We measured EAT, IAT, and IGFBP-1 from n = 102 participants from the LonGenity parent study at the Albert Einstein Institute of Aging, Bronx NY, who were enrolled to investigate healthy aging in Ashkenazi Jewish offspring of parents with exceptional longevity (OPEL) vs usual survival (OPUS). Participants underwent non-contrast electrocardiogram-gated computed tomography (CT) for fat volume quantification. Multiple linear regression models for the cross-sectional association of IGFBP-1 with EAT and IAT were adjusted for demographic, clinical, and laboratory factors.</div></div><div><h3>Results</h3><div>Higher IGFBP-1 levels were statistically significantly associated with lower EAT and IAT, particularly in the OPEL. This inverse relationship remained significant after adjusting for age, body mass index, high-density lipoprotein cholesterol, and cardiometabolic factors. In contrast, among the OPUS, the point estimates for these associations were directionally similar but not statistically significant.</div></div><div><h3>Conclusion</h3><div>Circulating IGFBP-1 may be a novel biomarker for visceral adiposity and cardiometabolic risk stratification. Future studies should explore its role in cardiovascular aging.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113099"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with preserved ejection fraction (HFpEF): translational mechanisms, diagnostic evolution and therapeutic frontiers 心力衰竭保留射血分数（HFpEF）：翻译机制，诊断演变和治疗前沿。

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-22 DOI: 10.1016/j.diabres.2026.113116

Lei Gao , Guofu Zhang , Kai Kang , Lei Xu , Wei Zhang , Chao Chi , Erjun Zhu , Taha Sheheryar , Bo Lv , Baodong Xie

{"title":"Heart failure with preserved ejection fraction (HFpEF): translational mechanisms, diagnostic evolution and therapeutic frontiers","authors":"Lei Gao , Guofu Zhang , Kai Kang , Lei Xu , Wei Zhang , Chao Chi , Erjun Zhu , Taha Sheheryar , Bo Lv , Baodong Xie","doi":"10.1016/j.diabres.2026.113116","DOIUrl":"10.1016/j.diabres.2026.113116","url":null,"abstract":"<div><div>Heart failure with preserved ejection fraction (HFpEF) is responsible for approximately half of global heart failure cases and is characterized by marked symptom burden, frequent hospitalization and limited disease-modifying options. Its biology extends beyond the ventricle into vascular, myocardial, metabolic and inflammatory pathways that converge to produce diastolic dysfunction and systemic remodeling. Diagnostic inconsistency and frequent need for exertional testing to unmask elevated filling pressures underscore residual gaps in recognition and targeted therapy. This review synthesizes contemporary evidence spanning epidemiology, mechanisms, diagnostic strategies and phenotype-directed management. Therapeutic advances comprise sodium glucose cotransporter-2 (SGLT2) inhibitors as foundational disease-modifying therapy, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as emerging adjunctive therapy for cardiometabolic HFpEF, structured exercise and lifestyle programs, hemodynamic-guided decongestion and ongoing evaluation of soluble guanylate cyclase (sGC) stimulators. Integrating these insights, HFpEF represents a family of endotypes unified by diastolic dysfunction but driven by distinct systemic mechanisms accounting for variable biomarker profiles and treatment responses. The priorities ahead center on linking human tissue biology with multi-omics and deep clinical phenotyping, standardization of diagnostic criteria, refinement of representative preclinical models and execution of biomarker-enriched, endotype-stratified trials to enable precision prevention and therapy in HFpEF.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113116"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of e-Health and artificial intelligence literacy levels on disease self-management in patients with diabetes 电子健康和人工智能素养水平对糖尿病患者疾病自我管理的影响

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-03 DOI: 10.1016/j.diabres.2026.113082

Nilhan Töyer Şahin , Seda Pehlivan

{"title":"The effects of e-Health and artificial intelligence literacy levels on disease self-management in patients with diabetes","authors":"Nilhan Töyer Şahin , Seda Pehlivan","doi":"10.1016/j.diabres.2026.113082","DOIUrl":"10.1016/j.diabres.2026.113082","url":null,"abstract":"<div><h3>Background</h3><div>This study was conducted to examine the effects of eHealth and artificial intelligence literacy on disease self-management in patients with diabetes.</div></div><div><h3>Methods</h3><div>The cross-sectional study was conducted with 212 patients with diabetes who were followed up in Endocrinology clinics and outpatient clinics of a hospital between October 2024 and June 2025. Data were collected through face-to-face interviews using a Personal Information Form, the eHealth Literacy Scale, the Artificial Intelligence (AI) Literacy Scale, and the Diabetes Self-Management Questionnaire. Data were analysed using the SPSS-27 software, and p = 0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>The mean age of the 212 patients was 52.09 ± 17.02, and their mean disease duration was 9.66 ± 8.47 years. The patients had mean Diabetes Self-Management Questionnaire, eHealth Literacy Scale, and AI Literacy Scale scores of 6.47 ± 1.50, 27.87 ± 8.83, and 48.12 ± 11.26, respectively.Diabetes self-management was significantly and positively correlated with eHealth literacy (r = 0.505; p = 0.000) and AI literacy (r = 0.499; p = 0.000). Additionally, a positive significant relationship was found between general eHealth literacy and AI literacy (r = 0.865; p = 0.000).</div></div><div><h3>Conclusions</h3><div>The results of this study suggest that general eHealth and AI literacy play a significant role in supporting diabetes self-management.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113082"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145905839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunometabolic reprogramming and β-cell dedifferentiation: Integrated mechanisms driving type 2 diabetes progression 免疫代谢重编程和β细胞去分化：驱动2型糖尿病进展的综合机制。

IF 7.4 3区医学

Diabetes research and clinical practice Pub Date : 2026-02-01 Epub Date: 2026-01-19 DOI: 10.1016/j.diabres.2026.113111

Ritu Dahiya, Ajay Pal Singh, Aruna Rawat

{"title":"Immunometabolic reprogramming and β-cell dedifferentiation: Integrated mechanisms driving type 2 diabetes progression","authors":"Ritu Dahiya, Ajay Pal Singh, Aruna Rawat","doi":"10.1016/j.diabres.2026.113111","DOIUrl":"10.1016/j.diabres.2026.113111","url":null,"abstract":"<div><div>Type 2 diabetes is increasingly recognised as a condition driven by sustained metabolic overload and chronic low-grade inflammation rather than a simple decline in insulin secretion. Findings from single-cell transcriptomics, human islet studies, and metabolic profiling show that pancreatic β-cells undergo progressive alterations in identity when exposed to glucotoxic, lipotoxic, oxidative, and inflammatory stress. In parallel, cytokines, lipid intermediates, adipose-derived factors, hepatokines, myokines, and gut microbial metabolites generate an immunometabolic environment that accelerates β-cell dedifferentiation and promotes transitions toward progenitor-like or alternative endocrine states. Originally described through lineage-tracing studies in experimental models, β-cell dedifferentiation is now recognized as a dynamic and potentially reversible process shaped by immunometabolic stress in diabetes. This review synthesizes current evidence to illustrate how metabolic and immune pathways converge on key molecular regulators of β-cell fate. It further describes how interorgan communication reinforces these disturbances and contributes to the gradual shift of β-cells along a continuum of stress adaptation, functional decline, and identity loss. A conceptual framework, referred to as the beta-cell identity clock, is presented to capture the dynamic and potentially reversible nature of these transitions. Finally, emerging therapeutic strategies are discussed, including anti-inflammatory agents, metabolic modulators, epigenetic regulators, and regenerative approaches aimed at preserving or restoring β-cell identity in the context of modern metabolic stress.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"232 ","pages":"Article 113111"},"PeriodicalIF":7.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0